TABLE 7.

Unmet clinical and research needs and knowledge gaps on HCV infection in patients with cancer

Optimal screening strategy in cancer patients and HCT recipients

Value of routine HCV screening in cancer centers

Need for systematic cancer screening of HCV-infected cancer patients to identify HCV-related second primary cancers

Optimal strategy for monitoring HCV infection during cancer treatment

Impact of DAA-based therapy in cancer prevention

Most favorable strategy for early detection and treatment of coinfections caused by carcinogenic viruses (e.g., hepatitis B virus, HIV, and human papillomavirus) in HCV-infected cancer patients

Studies on HBV reactivation in cancer patients with HBV and HCV co-infection receiving DAAs

Optimal timing of antiviral therapy in relation to chemotherapy and HCT

Efficacy and safety of various DAA regimens in cancer patients and HCT recipients

Predictors of liver disease progression, even if a SVR is achieved

Reliability of serologic markers of fibrosis and FibroScan VCTE in predicting the presence of advanced fibrosis and cirrhosis in cancer patients and HCT candidates

Inclusion of HCV-infected cancer patients in clinical trials of both cancer treatment and DAAs

Virologic, hepatic and oncologic impact of treating HCV in people with various cancers

Large well-designed prospective studies focused on cancer patients from distinct geographic areas analyzing the impact of geographic variations of HCV genotypes

Characterization of interactions between DAAs and chemotherapeutic agents

DAA, direct-acting antiviral; HBV, hepatitis B virus ; HCT, hematopoietic cell transplant; HCV, hepatitis C virus ; SVR, sustained virologic response; VCTE, vibration-controlled transient elastography